JP4188837B2 - Ｎｍｄａレセプターリガンドとしてのピリジン誘導体 - Google Patents

Ｎｍｄａレセプターリガンドとしてのピリジン誘導体 Download PDF

Info

Publication number
JP4188837B2
JP4188837B2 JP2003542174A JP2003542174A JP4188837B2 JP 4188837 B2 JP4188837 B2 JP 4188837B2 JP 2003542174 A JP2003542174 A JP 2003542174A JP 2003542174 A JP2003542174 A JP 2003542174A JP 4188837 B2 JP4188837 B2 JP 4188837B2
Authority
JP
Japan
Prior art keywords
formula
compound
pyridin
dihydro
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003542174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005513004A5 (https=
JP2005513004A (ja
Inventor
アラニン，アレキザンダー
ビュッテルマン，ベルント
ハイツ・ニダール，マリー−ポール
ピナール，エマニュエル
ワイラー，ルネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2005513004A publication Critical patent/JP2005513004A/ja
Publication of JP2005513004A5 publication Critical patent/JP2005513004A5/ja
Application granted granted Critical
Publication of JP4188837B2 publication Critical patent/JP4188837B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003542174A 2001-11-09 2002-11-02 Ｎｍｄａレセプターリガンドとしてのピリジン誘導体 Expired - Fee Related JP4188837B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126467 2001-11-09
PCT/EP2002/012240 WO2003040128A1 (en) 2001-11-09 2002-11-02 Pyridine derivatives as nmda receptor ligands

Publications (3)

Publication Number Publication Date
JP2005513004A JP2005513004A (ja) 2005-05-12
JP2005513004A5 JP2005513004A5 (https=) 2005-12-22
JP4188837B2 true JP4188837B2 (ja) 2008-12-03

Family

ID=8179179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003542174A Expired - Fee Related JP4188837B2 (ja) 2001-11-09 2002-11-02 Ｎｍｄａレセプターリガンドとしてのピリジン誘導体

Country Status (16)

Country Link
US (1) US6831087B2 (https=)
EP (1) EP1448547B1 (https=)
JP (1) JP4188837B2 (https=)
KR (1) KR100589995B1 (https=)
CN (1) CN100516061C (https=)
AR (1) AR037221A1 (https=)
AT (1) ATE293619T1 (https=)
AU (1) AU2002351816B8 (https=)
BR (1) BR0213977A (https=)
CA (1) CA2467973C (https=)
DE (1) DE60203820T2 (https=)
ES (1) ES2240829T3 (https=)
MX (1) MXPA04004308A (https=)
PL (1) PL369544A1 (https=)
RU (1) RU2303037C2 (https=)
WO (1) WO2003040128A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
RU2320654C1 (ru) * 2006-05-24 2008-03-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 2,2-ДИМЕТИЛ-4-(4,6-ДИМЕТИЛ-2-ПИРИДОН-3-ИЛ)-1,2-ДИГИДРО-БЕНЗО[f]ИЗОХИНОЛИНА ГИДРОХЛОРИД, ПРОЯВЛЯЮЩИЙ ПРЯМОЕ АНТИКОАГУЛЯНТНОЕ ДЕЙСТВИЕ
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8450327B2 (en) 2007-10-18 2013-05-28 Boehringer Ingelheim International Gmbh CGRP antagonists
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
CA2705405A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
JP2011504481A (ja) * 2007-11-22 2011-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物
EP2062889A1 (de) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
RU2438672C1 (ru) 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Агент, проявляющий свойства активатора когнитивных функций (варианты)
WO2025124571A1 (zh) * 2023-12-14 2025-06-19 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
EP1080074B1 (de) * 1998-05-25 2006-11-08 Abbott GmbH & Co. KG Heterocyclische substituierte Amide, deren Herstellung und Verwendung
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
DK1088818T3 (da) 1999-10-01 2005-03-14 Hoffmann La Roche Quinolin-4-yl-derivater
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
EP1448547A1 (en) 2004-08-25
BR0213977A (pt) 2004-08-31
CA2467973C (en) 2009-09-01
CN1585762A (zh) 2005-02-23
ES2240829T3 (es) 2005-10-16
MXPA04004308A (es) 2004-08-11
CA2467973A1 (en) 2003-05-15
JP2005513004A (ja) 2005-05-12
AR037221A1 (es) 2004-10-27
US6831087B2 (en) 2004-12-14
EP1448547B1 (en) 2005-04-20
WO2003040128A1 (en) 2003-05-15
US20030119870A1 (en) 2003-06-26
PL369544A1 (en) 2005-05-02
AU2002351816B8 (en) 2008-04-03
DE60203820D1 (de) 2005-05-25
RU2004117595A (ru) 2006-01-10
ATE293619T1 (de) 2005-05-15
AU2002351816B2 (en) 2008-03-06
DE60203820T2 (de) 2006-02-23
KR100589995B1 (ko) 2006-06-19
CN100516061C (zh) 2009-07-22
KR20050042252A (ko) 2005-05-06
RU2303037C2 (ru) 2007-07-20

Similar Documents

Publication Publication Date Title
JP4188837B2 (ja) Ｎｍｄａレセプターリガンドとしてのピリジン誘導体
EP3634958B1 (en) Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CN1277604A (zh) 在烟碱性乙酰胆碱受体上作为胆碱能配体的杂芳基二氮杂环烷类
TW200306180A (en) New compounds
SK70899A3 (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
WO2012036278A1 (ja) グリシントランスポーター阻害物質
AU2002351816A1 (en) Pyridine Substituted Isoquinoline Derivatives
JP2011225579A (ja) レニン阻害剤としての３，４−置換ピペリジン誘導体
CN108017641A (zh) 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
KR100591935B1 (ko) Ｎｍｄａ-수용체 아형 차단제로서의 피리딘 유도체
KR20220052333A (ko) 근위축성 측색 경화증 및 관련 장애의 치료를 위한 tdp-43에 결합하는 분자
NZ579735A (en) Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
CN115073370A (zh) 新型烷基氨类化合物或盐、异构体、其制备方法及用途
NZ251540A (en) Bridged bis-aryl carbinol derivatives, preparation and medicaments
WO1993019062A1 (en) Tetrahydropyridine isoxazoline derivatives
RU2330020C2 (ru) НОВЫЕ ПРОИЗВОДНЫЕ АМИНОПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGIuR5
KR20100119789A (ko) 2-아미노퀴놀린
AU2016378154B2 (en) Phenylimidazole compound
TW200410965A (en) Compounds
AU2002349396A1 (en) Pyridine derivatives as NMDA-receptor subtype blockers

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080909

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080911

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110919

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees